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Background: Numerous structurally unrelated drugs, including antipsychotics, can prolong QT interval and trigger
the acquired long QT syndrome (aLQTS). All of them are thought to act at the level of KCNH2, a subunit of the
potassium channel. Although the QT-prolonging drugs are proscribed in the subjects with aLQTS, the individual
response to diverse QT-prolonging drugs may vary substantially.
Case presentation: We report here a case of aLQTS in response to small doses of risperidone that was confirmed
at three independent drug challenges in the absence of other QT-prolonging drugs. On the other hand, the patient
did not respond with QT prolongation to some other antipsychotics. In particular, the administration of clozapine,
known to be associated with higher QT-prolongation risk than risperidone, had no effect on QT-length. A detailed
genetic analysis revealed no mutations or polymorphisms in KCNH2, KCNE1, KCNE2, SCN5A and KCNQ1 genes.
Conclusions: Our observation suggests that some patients may display a selective aLQTS to a single antipsychotic,
without a potassium channel-related genetic substrate. Contrasting with the idea of a common target of the
aLQTS-triggerring drugs, our data suggests existence of an alternative target protein, which unlike the KCNH2
would be drug-selective.
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The first cases of reversible QT prolongation upon ex-
posure to environmental stressors (mostly drugs) have
been described in the 1970s and designated as the
“acquired long QT syndrome” (aLQTS). The aLQTS-
triggering drugs are supposed to act at the subunit of
the potassium channel, the KCNH2, which produces the
delayed rectifier K(+) current (I(Kr)) [1]. The KCNH2 is
blocked by numerous structurally unrelated drugs
(antipsychotics and antiarrhythmics) that affect cardiac
repolarization [2-4]. Although the effect of this blockage
is clinically irrelevant in general population, in a small
proportion of subjects, otherwise asymptomatic, the
presence of mutations in the KCNH2 or other function-
ally related genes potentiates the effect of these drugs
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reproduction in any medium, provided the oraLQTS [5-7]. Given the serious health repercussions of
this phenomenon, the aLQTS-triggering drugs are all
proscribed in these vulnerable individuals, since they are
supposed to have a common mechanism of QT-
prolongation.
However, we describe here a patient, who in the ab-
sence of genetic alterations in the LQTS-related genes,
selectively responds with QT prolongation to risperidone
only. This observation suggests the presence of an alter-
native target protein that unlike the KCNH2 would be
drug-selective.
Case report
We report here a case of 37-year old woman with
schizophrenia, hospitalized for an exacerbation of psych-
otic symptoms. She had no personal/family history of
cardiac diseases or sudden deaths. Besides benzodiaze-
pines, she was treated at the admission with aripiprazol
(20 mg/day), haloperidol (3 mg/day) and escitalopram
(20 mg/day). The routine laboratory and clinical check-
up (including ECG and blood electrolytes) revealed noal Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
Lazarczyk et al. BMC Psychiatry 2012, 12:220 Page 2 of 4
http://www.biomedcentral.com/1471-244X/12/220abnormalities. The patient developed the aLQTS in
response to small doses of risperidone (1–2 mg/day),
confirmed at three independent drug challenges. Note-
worthy, the patient responded with significant QT pro-
longation to risperidone (QTc increase from 458 to 508
ms), also when all other drugs, which might potentially
affect QT length, were discontinued (Figure 1A). The
reason of this extreme sensitivity to risperidone was un-
clear but the contribution of a cytochrome polymor-
phism or other elimination failures is unlikely since
risperidone prolonged QT at very low blood concen-
trations (19.1 nM). Moreover, the concentration of
paliperidone, an active metabolite of risperidone with
QT-prolonging potential [8], was very low too, and the
cumulative blood concentration of risperidone andhaloperidol
aripiprazol
escitalopram
risperidone
A
C
Figure 1 A. Risperidone induces QT prolongation. ECG at the admissio
formula) was not prolonged under the treatment of aripiprazol (20 mg/day
the QTc value was monitored regularly. At day 4, 9 and 15 risperidone (2 x
or 15, respectively, as indicated on the graph. Other antipsychotics/antidep
prolongation was observed each time when risperidone was introduced, e
immediately after the risperidone treatment was stopped. B. Comparative
length. QTc values have been measured during the treatment with progre
risperidone (1 – 2 mg; n=3) or in the absence of these drugs (control; n=8
prolongation in this patient, as assessed by Mann–Whitney U test. NS – sta
clozapine and risperidone in relation to KCNH2 IC50. Drug plasma con
clozapine, or the second day after its introduction, for risperidone (2 x 1 m
the graph, the drug concentrations have been expressed as a fold of their
clozapine, and 148 nM for risperidone), previously determined for these dru
clozapine, significantly prolonged QT length.paliperidone was subtherapeutic. Interestingly, the pa-
tient did not respond with QT prolongation following
the administration of other antipsychotics (e.g. aripipra-
zol, clothiapine, haloperidol; data not depicted). In par-
ticular, the administration of clozapine, known to be
associated with higher QT-prolongation risk than risper-
idone [9], had no effect on QT-length (Figure 1B).
We hypothesized that our patient carries a mutation
or polymorphism in the KCNH2, which could determine
conformational alterations of the channel and thus dif-
ferentially affect its capacity to bind risperidone and clo-
zapine. Therefore, we have sequenced all the coding
exons and exon-intron boundaries of the KCNH2 (iso-
forms 1a and 1b), but no mutation or polymorphism
was found (data not depicted). We have also excludedp<0.01
p=0.01
NS
B
n was normal and the corrected QT value (QTc; according to the Bazett
), haloperidol (3 mg/day) and escitalopram (20 mg/day). Subsequently,
1 mg/day) was introduced and thereafter rapidly stopped at day 4, 10
ressant were discontinued, as indicated on the graph. QTc
ven after a single 1 mg dose, and it returned to the normal range
analysis of the impact of risperidone and clozapine on QT
ssively increasing doses of clozapine (12,5 – 275 mg; n=14),
). Risperidone but not clozapine caused statistically significant QTc
tistically not significant. C. Plasma concentration of aripiprazol,
centration has been determined at the steady state, for aripiprazol and
g/day), at the time of the predicted peak of the plasma drug level. On
respective KCNH2 IC50values (263 nM for aripiprazol, 320 nM for
gs. At the indicated concentrations, risperidone, but not aripiprazol or
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KCNE2 (data not depicted), the gene encoding the β–
subunit of the Ikr channel, as well as G38S and D85N
polymorphism in the KCNE1, reported to cause the
LQTS [10,11]. Since a subtle mutation in the KCNQ1
could affect the repolarisation reserve, indirectly leading
to the aLQTS [12,13], we have sequenced also this gene
but found no mutation (data not depicted). Additionally,
we have excluded any exonic deletion and duplication of
the KCNH2 by Multiplex Ligation-dependent Probe
Amplification (data not depicted; P114-A2-LQT probe-
mix, MRC-Holland).
Conclusions
The QT prolongation in our patient fulfills the criteria
for aLQTS. However, because of its striking drug-select-
ivity, we use the term “selective acquired long QT syn-
drome” (saLQTS). The present report indicates that
some patients with drug-induced LQTS display in fact
the saLQTS and would tolerate perfectly well certain
KCNH2 blockers. Even though the saLQTS has not pre-
viously been reported, we suppose that its prevalence
among the patients displaying drug-induced long QT
could be underestimated since the response to diverse
QT-prolonging drugs within the same subjects is only
rarely investigated.
The molecular mechanism of the saLQTS in the
reported case remains challenging. Since risperidone
scarcely prolongs QTc (< 4 ms) in a general population
(with a priori a wild-type KCNH2) [14], the sensitivity to
this drug in our patient (also carrying only wild-type
alleles of this gene) is most probably not mediated by
the KCNH2. Despite having sequenced the gene we still
cannot formally exclude a defect affecting the expres-
sion, trafficking, and cellular localization of the protein.
However, it is highly unlikely that such a defect would
selectively affect its interaction only with risperidone. It
is also noteworthy that risperidone prolonged QT
already at concentration much lower than its KCNH2
IC50 (half maximal inhibitory concentration), whereas
other antipsychotics had no impact on QT in this pa-
tient, even at concentrations up to 6-times higher than
their KCNH2 IC50 values (Figure 1C).
Sequencing of some other genes implicated in the
pathogenesis of LQTS did not reveal any significant mu-
tation or polymorphism in our patient, and exact mo-
lecular mechanism of the reported saLQTS remains
unknown. Admittedly, it cannot be formally excluded
that further expanding of genetic screening on all of the
genes implicated in the LQTS could lead to the identifi-
cation of causative mutations. However, this seems ra-
ther unlikely, since the mutations in the five most
important genes that we have already sequenced
(KCNH2, KCNQ1, KCNE1, KCNE2 and SCN5A) areresponsible for probably more than 95% of the cases of
LQTS with known genetic background [15].
Taken together, these data imply the presence of a
KCNH2-independent pathway leading to aLQTS. Al-
though mutations in several genes have already been
reported in this condition [7], it has been long consid-
ered that the corresponding proteins do not constitute a
drug target but they rather modulate an outcome of the
drug-KCNH2 interactions. Contrasting with this idea,
our data suggest the existence of an alternative target
protein, which unlike the KCNH2 would be drug-
selective.
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